Posts tagged Phase 2 clinical trial
RepliCel details go-forward strategy

RepliCel Life Sciences (OTCQB:REPCF; TSXV:RP; FRA:P6P2) has formulated a strategic plan for 2017 through 2019 focused on maturing its assets through three distinct pillars.

Read More
Galectin completes patient recruitment in NASH trial

Galectin Therapeutics (NASDAQ:GALT) has completed patient recruitment in its Phase 2 clinical trial with GR-MD-02 in patients with non-alcoholic steatohepatitis (NASH) with cirrhosis, the NASH-CX trial. The company expects to report the topline results of the trial in December 2017.

Read More
Can-Fite unit fails Phase 2 glaucoma trial

Can-Fite BioPharma’s (NYSE MKT:CANF; TASE:CFBI) subsidiary, OphthaliX (OTC:OPLI) released top-line results from its Phase 2 clinical trial of CF101 for the treatment of glaucoma.

No statistically significant differences were found between the CF101 treated group and the placebo group in the primary endpoint of lowering intra ocular pressure (IOP). High IOP is a characteristic of glaucoma. CF101 was found to have a favorable safety profile and was well tolerated.

Read More